aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Immunome, a Philadelphia-based biotech company, focuses on developing innovative cancer immunotherapies. Leveraging the human immune system, Immunome aims to create a robust pipeline of treatments to combat various types of cancer, addressing a critical need in the healthcare market.
Immunome has made significant strides in biotechnology, contributing to advancements in cancer treatment. Their pioneering work in immunotherapies has positioned them as a key player in the biotech industry, with a growing impact on patient care and medical research.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Immunome founded?
Immunome was founded in 2008.
Where is Immunome's headquarters located?
Immunome's headquarters is located in Exton, PA, US.
When was Immunome's last funding round?
Immunome's most recent funding round was for $125M (USD) in June 2023.
How many employees does Immunome have?
Immunome has 48 employees as of Feb 6, 2024.
How much has Immunome raised to-date?
As of July 05, 2023, Immunome has raised a total of $218.9M (USD) since Jun 29, 2023.
Add Comparison
Total Raised to Date
$218.9M
USD
Last Update Jun 29, 2023
Last Deal Details
$125M
USD
Jun 29, 2023
Post Ipo Equity
Total Employees Over Time
48
As of Feb 2024
Immunome Address
665 Stockton Drive
Suite 300
Exton,
Pennsylvania
19341
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts